Company Overview of HUYA Bioscience International, LLC
HUYA Bioscience International, LLC engages in identifying and licensing pre-clinical and clinical stage compounds in China. It engages in accelerating the development of biopharmaceutical product opportunities originating in China. The company offers HBI-8000, a histone deacetylases inhibitors for cancer; HBI-3000, a multi-ion channel blocker for the treatment of arrhythmia; and HBI-3802, a small molecule for improving heart function, as well as stimulates cardiac stem cell differentiation into functional cardiomyocytes, and replaces and remodels dead myocardium with new functional tissues. The company has a strategic alliance with China Wuqing Development Area. HUYA Bioscience International...
12531 High Bluff Drive
San Diego, CA 92130
Founded in 2004
Key Executives for HUYA Bioscience International, LLC
Founder, Executive Chairman, Chief Executive Officer and President
Chief Technology Officer and Chief Operating Officer of Asia
Chief Scientific Officer and Executive Vice President
Head of Therapeutics China
Compensation as of Fiscal Year 2015.
HUYA Bioscience International, LLC Key Developments
HUYA Bioscience International Announces Appointment of Yoshiki Shimamura as Vice President for Japan Operations
Jun 30 15
HUYA Bioscience International announced an expansion of its Senior Management Team, with the appointment of Yoshiki Shimamura as Vice President for Japan Operations. Mr. Shimamura has more than 25 years of experience in the biopharma industry and clinical research organizations in Japan and South Korea, including companies such as Novocure KK, Hospira Japan Co Ltd, Chong Kun Dang Pharmaceutical Co, Amgen and Taiho Pharmaceutical Co Ltd.
HUYA Bioscience International Appoints Bob Goodenow as Chief Business Officer
Jun 16 15
HUYA Bioscience International announced that it is further strengthening its Executive Team with the appointment of Bob Goodenow, Ph.D., as Chief Business Officer. Dr. Goodenow has more than 25 years of senior management experience in the biotech and pharmaceutical industries, spanning research and development, marketing and business development. Most recently, Dr. Goodenow was Chief Business Officer at Syndax Pharmaceuticals. Previously, he was Vice President, Corporate Development, at Inovio Biomedical and held numerous senior level positions in Corporate Marketing, Business Development, and Research and Development for RPR, Aventis and Baxter Healthcare.
HUYA Bioscience International Completes First Cohort in Phase 1 Clinical Trial of HBI-8000 in Japan
Mar 19 15
HUYA Bioscience International has completed the first cohort in a Phase 1 clinical trial in Japan of its cancer drug HBI-8000, a novel oral histone deacetylase inhibitor. This follows acceptance by the Pharmaceutical and Medical Devices Agency (PMDA) of the company's accelerated development strategy in Japan. The Phase 1 open-label, dose escalation trial is evaluating the safety and pharmacokinetics of HBI-8000 in Japanese patients with non `Hodgkin's lymphoma. The first cohort received HBI-8000 tablets twice weekly, with no dose-limiting toxicities observed. The second cohort is now underway with a higher dose. The trial is designed to establish a maximum tolerated dose (MTD) to proceed to Phase 2 trials for the treatment of adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) in Japan. The clinical development of HBI-8000 in Japan leverages clinical data from Chinese clinical trials through the Tripartite Cooperation on Health between China, South Korea and Japan. Shenzhen Chipscreen Biosciences recently announced the approval of chidamide in China as the world's first oral HDAC inhibitor for the treatment of relapsed or refractory PTCL. HUYA holds exclusive rights to chidamide (HBI-8000) worldwide, excluding China, and is developing the compound for hematological malignancies and solid tumors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|